Free Trial
→ The DOJ Just Paved the Way for Account Seizures (From Priority Gold) (Ad)
NASDAQ:TELO

Telomir Pharmaceuticals 5/12/2025 Earnings Report

Telomir Pharmaceuticals logo
$1.64 -0.07 (-3.82%)
As of 12:58 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.
ProfileEarnings HistoryForecast

Telomir Pharmaceuticals EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.10
Beat/Miss
Beat by +$0.03
One Year Ago EPS
N/A

Telomir Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Telomir Pharmaceuticals Announcement Details

Quarter
Date
5/12/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Telomir Pharmaceuticals' next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Telomir Pharmaceuticals Earnings Headlines

Telomir Pharmaceuticals Reports Positive Preclinical Data
June 18, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/telomir-pharmaceuticals-reports-positive-preclinical-data?utm_source=marketbeat.com&utm_medium=referral
TELO Rises on Promising Telomir-1 Preclinical Results
June 13, 2025  |  insidermonkey.comhttps://www.insidermonkey.com/blog/telo-rises-on-promising-telomir-1-preclinical-results-1551841/
The DOJ Just Paved the Way for Account Seizures
Washington is running out of money…And guess where they'll look next? When governments go broke, they take from the people. It's happened before, and it's happening again. The Department of Justice just admitted that cash isn't legally YOUR property.
June 27 at 2:00 AM  |  Priority Gold (Ad)
TELO Rises on Promising Telomir-1 Preclinical Results
June 13, 2025  |  msn.comhttps://www.msn.com/en-us/money/general/telo-rises-on-promising-telomir-1-preclinical-results/ar-AA1GFLw3
TELO Continues Trend of Significant Trial Announcements
June 11, 2025  |  msn.comhttps://www.msn.com/en-us/money/savingandinvesting/telo-continues-trend-of-significant-trial-announcements/ar-AA1Gwwtq
Telomir Pharmaceuticals Announces Telomir-1 Resets the Body’s Epigenetic Clock, Reverses DNA Methylation, and Restores Youthful Gene Regulation in an Ultra-Rare Accelerated ...
June 7, 2025  |  usatoday.comhttps://www.usatoday.com/press-release/story/7262/telomir-pharmaceuticals-announces-telomir-1-resets-the-bodys-epigenetic-clock-reverses-dna-methylation-and-restores-youthful-gene-regulation-in-an-ultra-rare-accelerated-aging-animal-model-of-wern/
See More Telomir Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Telomir Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telomir Pharmaceuticals and other key companies, straight to your email.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals (NASDAQ:TELO), a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

View Telomir Pharmaceuticals Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles